The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 11, 2004, Pages 649-656

  Gao, Zairong ^a   Biersack, Hans J ^b   Ezziddin, Samer ^b   Logvinski, Timur ^b   An, Rui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Medullary thyroid cancer; MIBG; Octreotide; Radionuclide therapy; Scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANTINEOPLASTIC AGENT; OCTREOTIDE[1,4,7 TETRAAZACYCLODODECAN 4,7,10 TRICARBOXYMETHYL 1 YLACETYL 1 DEXTRO PHENYLALANINE 3 TYROSINE Y 90]; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; REMISSION; SCINTISCANNING; SIDE EFFECT; THYROID MEDULLARY CARCINOMA;

3-IODOBENZYLGUANIDINE; ADULT; CARCINOMA, MEDULLARY; FEMALE; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; OCTREOTIDE; PATIENT SELECTION; PENTETIC ACID; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 8644273965     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0588-1     Document Type: Article

References (34)

1. Abdelmoumene N, Schlumberger M, Gardet P, Roche A, Travagli JP, Francese C, Parmentier C (1994) Selective venous sampling catheterization for localization of persisting medullary thyroid carcinoma. Br J Cancer 69:1141-1144
2. Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hor G (1998) Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 25:1277-1283
3. Arslan N, Ilgan S, Yuksel D, Serdengecti M, Bulakbasi N, Ugur O, Ozguven MA (2001) Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med 26:683-688
4. Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP, Parmentier C (1996) Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 37:912-916
5. Brunt LM, Wells SA Jr (1987) Advances in the diagnosis and treatment of medullary thyroid carcinoma. Surg Clin North Am 67:263-279
6. de Jong M, Krenning E (2002) New advances in peptide receptor radionuclide therapy. J Nucl Med 43:617-619
7. DeLellis RA, Rule AH, Spiler I, Nathanson L, Tashjian AH Jr, Wolfe HJ (1978) Calcitonin and carcinoembryonic antigen as tumour markers in medullary thyroid carcinoma. Am J Clin Pathol 70:587-594
8. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grunwald F (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28:1671-1676
9. Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E (1992) Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: results of a compartment-oriented microdissection method. Henry Ford Hosp Med J 40:264-267
10. Frank-Raue K, Raue F, Buhr HJ, Baldauf G, Lorenz D, Ziegler R (1992) Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid 2:113-117
11. Hanna FWF, Ardill JES, Johnston CF, Cunningham RT, Curry WJ, Russell CF, Buchanan KD (1997) Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid. J Endocrinol 152:275-281
12. Hoefnagel CA (1994) Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumors. Eur J Nucl Med 21:561-581
13. Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A national cancer data base report of 53,856 cases of thyroid carcinomas treated in the U.S. 1985-1995. Cancer 83:2638-2648
14. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB (2001) Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86:895-902
15. Krausz Y, Rosler A, Guttmann H, Ish-Shalom S, Shibley N, Chisin R, Glaser B (1999) Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid. Clin Nucl Med 24:256-260
16. 1-octreotide and technetium-99m (V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma. J Nucl Med 39:1907-1909
17. Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, Krenning EP (1993) In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 76:1413-1417
18. 0]octreotide in patients. Eur J Nucl Med 28:1319-1325
19. 131I-meta-iodobenzylguanidine scintigraphy and selective venous catheterization after thyroidectomy for medullary thyroid carcinoma. Med Oncol Tumor Pharmacother 8:7-13
20. Lupoli G, Cascone E, Arlotta F, Vitale G, Celentano L, Salvatore M, Lombardi G (1996) Treatment of advanced medullary thyroid carcinoma with a combination of recombination interferon alpha-2b and octreotide. Cancer 78:1114-1118
21. Marsh DJ, Learoyd DL, Robinson BG (1995) Medullary thyroid carcinoma: recent advances and management update. Thyroid 5:407-424
22. Oeberg K (1998) Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 10:58-65
23. 131I-meta-iodobenzylguanidin in medullary thyroid carcinoma. Endocrinol Jpn 33:309-315
24. Oosterom R, Verleun T, Bruining HA, Hackeng WH, Lamberts SW (1987) Human medullary thyroid carcinoma in tissue culture: secretion of calcitonin and carcinoembryonic antigen. J Endocrinol Invest 10:117-121
25. O'Riordain DS, O'Brien T, Crotty TB, Gharib H, Grant CS, van Heerden JA (1995) Multiple endocrine neoplasia type 2b: more than an endocrine disorder. Surgery 118:936-942
26. Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC (2001) Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 54:641-649
27. Raue F, Winter J, Frank-Raue K, Lorenz D, Herfarth C, Ziegler R (1989) Diagnostic procedure before reoperation in patients with medullary thyroid carcinoma. Horm Metab Res Suppl 21:31-34
28. Rufini V, Salvatori M, Garganese MC, Di Giuda D, Lodovica Maussier M, Troncone L (2000) Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 25:273-282
29. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE (1992) A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13:513-521
30. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66-71
31. 131I-MIBG therapy of neural crest tumors. Anticancer Res 17:1823-1832
32. 3-octrotide: a pilot study. Nucl Med Commun 22:673-678
33. 90Y-DOTATOC. J Nucl Med 43:610-616
34. Wang Q, Takashima S, Fukuda H, Takayama F, Kobayashi S, Sone S (1999) Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 125:842-848